Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Synaptic vesicle protein 2A (SV2A) is an integral membrane protein necessary for the proper function of the central nervous system and is associated to the physiopathology of epilepsy. SV2A is the molecular target of the anti-epileptic drug levetiracetam and its racetam analogs. The racetam binding site in SV2A and the non-covalent interactions between racetams and SV2A are currently unknown; therefore, an in silico study was performed to explore these issues. Since SV2A has not been structurally characterized with X-ray crystallography or nuclear magnetic resonance, a three-dimensional (3D) model was built. The model was refined by performing a molecular dynamics simulation (MDS) and the interactions of SV2A with the racetams were determined by docking studies. A reliable 3D model of SV2A was obtained; it reached structural equilibrium during the last 15 ns of the MDS (50 ns) with remaining structural motions in the N-terminus and long cytoplasmic loop. The docking studies revealed that hydrophobic interactions and hydrogen bonds participate importantly in ligand recognition within the binding site. Residues T456, S665, W666, D670 and L689 were important for racetam binding within the trans-membrane hydrophilic core of SV2A. Identifying the racetam binding site within SV2A should facilitate the synthesis of suitable radio-ligands to study treatment response and possibly epilepsy progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
I-TASSER server for protein 3D structure prediction
Zhang, Y. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-40 · Cited by 5,124
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 3×
“SV2A is the molecular target of the second-generation antiepileptic drug LEV and its structural analogs BRIV, SEL and UCB-30889 (Gillard et al., 2003; Lynch et al., 2004; Frycia et al., 2010).”
BackgroundAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1×
“The SV2A protein has been associated to the physiopathology of epilepsy; newborn mice lacking SV2A experience severe seizures and die within 3 weeks, suggesting multiple neural alterations (Crowder et al., 1999; Janz et al., 1999).”
BackgroundSV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256
SV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212
SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis
Chang, W.-P., & Südhof, T. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-08.2009 · Cited by 176 · cited 1×
“It regulates vesicle exocytosis by modulating the concentration of pre-synaptic calcium (Janz et al., 1999; Chang and Sudhof, 2009; Wan et al., 2010); maybe by binding to synaptotagmin 1 (Schivell et al., 1996, 2005; Yao et al., 2010), a calcium sensor protein implicated in synaptic vesicle…”
BackgroundCotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · cited 1×
“…vesicle exocytosis by modulating the concentration of pre-synaptic calcium (Janz et al., 1999; Chang and Sudhof, 2009; Wan et al., 2010); maybe by binding to synaptotagmin 1 (Schivell et al., 1996, 2005; Yao et al., 2010), a calcium sensor protein implicated in synaptic vesicle exocytosis.”
BackgroundSV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138 · cited 5×
“Tryptophan 666 is conserved in all SV2 isoforms and is homologous to a tryptophan in the 10th TM domain of MFS transporters which is vital for their activity (Nowack et al., 2010; Shi et al., 2011).”
BackgroundInfluentialSynaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124
Self-citation
Cited by
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
“[87] built a complete model of the SV2A protein with levetiracetam, along with other racetams (brivaracetam and seletracetam) docked into it.”
BackgroundLevetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“port the putative LBS observed previously [106] where the residues found by single”
BackgroundSelf-citationSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
“A combination of theoretical and experimental approaches helped the identification of a series of amino acidic residues possibly involved in the racetams binding to SV2A, localized in transmembrane regions of the protein (Shi et al., 2011; Correa-Basurto et al., 2015).”
BackgroundTokudome, K., Okumura, T., Shimizu, S., Mashimo, T., Takizawa, A., Serikawa, T., Terada, R., Ishihara, S., Kunisawa, N., Sasa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep27420 · Cited by 75
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
Metadata
- Authors
- Correa-Basurto, J., Cuevas-Hernández, R. I., Phillips-Farfán, B. V., MartÃnez-Archundia, M., Romo-Mancillas, A., RamÃrez-Salinas, G. L., Pérez-González, Ã. A., Trujillo-Ferrara, J., & Mendoza-Torreblanca, J. G.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-04-10
- Volume
- 9
- Pages
- 125-125
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2014054304
- Cited by
- 40
- References
- 9
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. https://app.cochat.ai/papers/10.3389/fncel.2015.00125
- The paper
- Correa-Basurto, J., Cuevas-Hernández, R. I., Phillips-Farfán, B. V., MartÃnez-Archundia, M., Romo-Mancillas, A., RamÃrez-Salinas, G. L., Pérez-González, Ã. A., Trujillo-Ferrara, J., & Mendoza-Torreblanca, J. G. (2015). Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2015.00125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.